The common
PNPLA3 (adiponutrin) variant, p.I148M, was identified as a genetic determinant of liver fibrosis. Since the expression of
PNPLA3 is induced by sterol regulatory element binding protein 1c (SREBP1c), we investigate two common
SREBP1c variants (rs2297508 and rs11868035) for their association with
[...] Read more.
The common
PNPLA3 (adiponutrin) variant, p.I148M, was identified as a genetic determinant of liver fibrosis. Since the expression of
PNPLA3 is induced by sterol regulatory element binding protein 1c (SREBP1c), we investigate two common
SREBP1c variants (rs2297508 and rs11868035) for their association with liver stiffness. In 899 individuals (aged 17–83 years, 547 males) with chronic liver diseases, hepatic fibrosis was non-invasively phenotyped by transient elastography (TE). The
SREBP1c single nucleotide polymorphisms (SNPs) were genotyped using PCR-based assays with 5'-nuclease and fluorescence detection. The
SREBP1c rs11868035 variant affected liver fibrosis significantly (
p = 0.029): median TE levels were 7.2, 6.6 and 6.0 kPa in carriers of (TT) (
n = 421), (CT) (
n = 384) and (CC) (
n = 87) genotypes, respectively. Overall, the
SREBP1c SNP was associated with low TE levels (5.0–8.0 kPa). Carriers of both
PNPLA3 and
SREBP1c risk genotypes displayed significantly (
p = 0.005) higher median liver stiffness, as compared to patients carrying none of these variants. The common
SREBP1c variant may affect early stages of liver fibrosis. Our study supports a role of the SREBP1c-PNPLA3 pathway as a “disease module” that promotes hepatic fibrogenesis.
Full article